European Council for
Cardiovascular Research

ACE2 – a receptor for SARS-CoV2

APEIRON Biologics Initiates Phase II Clinical Trial of APN01, the recombinant form of the human angiotensin-converting enzyme 2 (rhACE2), for Treatment of COVID-19. https://pipelinereview.com/index.php/2020040274194/Proteins-and-Peptides/APEIRON-Biologics-Initiates-Phase-II-Clinical-Trial-of-APN01-for-Treatment-of-COVID-19.html

Hoffmann et al. SARS-CoV-Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Mar 4. pii: S0092-8674(20)30229-4. doi: 10.1016/j.cell.2020.02.052. https://www.ncbi.nlm.nih.gov/pubmed/32142651

Shang et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020 Mar 30. doi: 10.1038/s41586-020-2179-y. https://www.ncbi.nlm.nih.gov/pubmed/32225175

Lan et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020 Mar 30. doi: 10.1038/s41586-020-2180-5.  https://www.ncbi.nlm.nih.gov/pubmed/32225176

Ou et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620. doi: 10.1038/s41467-020-15562-9. https://www.ncbi.nlm.nih.gov/pubmed/32221306

Cao Y, et a. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020 Feb 24;6:11. doi: 10.1038/s41421-020-0147-1. eCollection 2020. https://www.ncbi.nlm.nih.gov/pubmed/32133153

Zhang H et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3. https://www.ncbi.nlm.nih.gov/pubmed/32125455

Xu et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020 Feb 24;12(1):8. doi: 10.1038/s41368-020-0074-x. https://www.ncbi.nlm.nih.gov/pubmed/32094336

Delanghe et al. The host’s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin Chim Acta. 2020 Mar 24;505:192-193. doi: 10.1016/j.cca.2020.03.031. https://www.ncbi.nlm.nih.gov/pubmed/32220422

Sun et al. CD-sACE2 Inclusion Compounds: An Effective Treatment for Corona Virus Disease 2019 (COVID-19). J Med Virol. 2020 Mar 31. doi: 10.1002/jmv.25804. https://www.ncbi.nlm.nih.gov/pubmed/32232976

Zou et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020 Mar 12. doi: 10.1007/s11684-020-0754-0. https://www.ncbi.nlm.nih.gov/pubmed/32170560

Li et al. Analysis of angiotensin-converting enzyme 2 (ACE2) from different species sheds some light on cross-species receptor usage of a novel coronavirus 2019-nCoV. J Infect. 2020 Apr;80(4):469-496. doi: 10.1016/j.jinf.2020.02.013. Epub 2020 Feb 21. https://www.ncbi.nlm.nih.gov/pubmed/32092392